Company intelligence / Profile preview

RegeneCure

Jerusalem, Jerusalem District, Israelprnewswire.com ↗

Ownership: Private
Development stage: Phase 1

Overview

RegeneCure has initiated at least two clinical studies evaluating its proprietary synthetic bone-stimulating membranes for applications in dental implants and orthopedic fracture repair. Early-stage results are focused on safety and efficacy of guided bone regeneration using their AMCA GBR Dental Membrane. No late-stage or commercial data available yet.

Therapeutic areas: OtherRheumatologyNeurology
Modalities: DeviceBiomaterialHydrogel-based drug delivery therapy
Industry: Implantable Medical Devices

Drug pipeline

2 assets

AMCA GBR Dental Membrane

Phase 1

Indications: Dental implants, Bone regeneration

1 more asset in the full pipeline.

Request access →

Partnerships

Hadassah Medical Organization

Beyond the preview

Go deeper on RegeneCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RegeneCure.

Explore the full profile